BioWorld

Aug. 21, 2008

View Archived Issues

PDL Could Get $1.2B from BMS for Two Early Stage Antibodies

After struggling through a year of shifting business strategies, PDL BioPharma Inc. signed an antibody deal with Bristol-Myers Squibb Co. that could be worth nearly $1.16 billion. (BioWorld Today) Read More

Myriad Considers Splitting Itself After Flurizan Flop

Read More

Neurogenesis 'Funnel': Where Antidepressants Converge

Read More

Aposense Raises $13.3M for Apoptosis Technology

Read More

Other News To Note

Read More

Clinic Roundup

Read More